S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
XERS · Xeris Biopharma Holdings, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Xeris Biopharma Holdings Inc (XERS)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$10.78
-0.34
(-3.06%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$10.78
$10.78
$11.28
52-WEEK RANGE
$10.78
$5.25
$11.41
What's happening
- XERS is down 3.06% today, trading at $10.78. — Live quote
- Volume today (126,078) is well below its 3-month average of 2,270,070. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.18 actual vs. $0.00 estimated (-5394.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
XERS
+41.78%
vs S&P 500
+29.01%
1-YEAR RETURN
XERS
+19.16%
vs S&P 500
+4.60%
6-MONTH RETURN
XERS
+81.86%
3-MONTH RETURN
XERS
+26.77%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.18
Est. $0.00
MISS -5394.1%
2026-04-26 (Q1 2026)
$0.01
Est. $-0.01
BEAT +217.6%
2026-01-26 (Q4 2025)
$0.06
Est. $0.04
BEAT +33.6%
2025-10-26 (Q3 2025)
$0.00
Est. $0.00
MISS -100.0%
Valuation Measures & Ratios
Enterprise Value4$2.36B
Forward P/E541.41
PEG Ratio6—
Price / Sales (TTM1)6.65
Price / Book776.87
EV4 / Revenue7.04
EV4 / EBITDA141.78
Profit Margin-5.12%
Operating Margin1.73%
Return on Equity (ROE8)99.74%
Return on Assets (ROA9)-4.41%
Avg Volume (3M)2,270,070
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.37B | $1.29B | — | $902.3M | $841.3M |
| P/E | -45.35 | -156.11 | — | -21.54 | -14.27 |
| Price/Sales | 4.26 | 4.48 | — | 3.86 | 4.14 |
| Price/Book | -140.58 | 99.50 | — | -46.74 | -23.95 |
| EV/Revenue | 4.67 | 4.86 | — | 4.54 | 4.99 |
| EV/EBITDA | 58.51 | 80.91 | — | — | — |
| ROE | 309.99% | -63.74% | — | 217.01% | 167.79% |
| ROA | -7.33% | -2.12% | — | -12.52% | -18.69% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,202,379
Change from Prior Settlement-10.63%
% of Float—
Days to Cover (Short Ratio)1.74
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 28.7% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +19.2%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -5.1%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on XERS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92.1M | $83.1M | $74.4M | $71.5M | $60.1M | $54.3M | $48.1M | $40.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $5.2M | $7.9M | $6.7M | $4.5M | -$3.1M | -$12.9M | -$8.2M | -$14.2M |
| Net income | -$31.1M | $2.2M | $621.0K | -$1.9M | -$9.2M | -$15.7M | -$15.0M | -$19.0M |
| EPS (diluted) | $-0.18 | $0.01 | $0.00 | $-0.01 | $-0.06 | $-0.11 | $-0.10 | $-0.14 |
| EPS (basic) | $-0.18 | $0.01 | $0.00 | $-0.01 | $-0.06 | $-0.11 | $-0.10 | $-0.14 |
| Operating margin | $6 | $10 | $9 | $6 | -$5 | -$24 | -$17 | -$35 |
| Net margin | -$34 | $3 | $1 | -$3 | -$15 | -$29 | -$31 | -$47 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $411.9M | $392.0M | $383.5M | $370.2M | $334.7M | $315.5M | $323.1M | $321.1M |
| Total liabilities | $421.6M | $379.0M | $369.8M | $371.1M | $354.0M | $350.6M | $352.7M | $349.4M |
| Stockholders' equity | -$9.7M | $13.0M | $13.7M | -$861.0K | -$19.3M | -$35.1M | -$29.6M | -$28.3M |
| Total current assets | $274.8M | $251.7M | $240.3M | $224.0M | $185.6M | $163.5M | $167.7M | $162.8M |
| Total current liabilities | $189.6M | $118.6M | $109.6M | $116.2M | $95.2M | $95.1M | $100.4M | $91.0M |
| Cash & equivalents | $121.7M | $111.8M | $111.0M | $91.6M | $59.3M | $58.4M | $71.6M | $59.2M |
| Marketable securities (current) | — | — | — | — | — | — | $0 | $10.2M |
| Accounts receivable | $58.1M | $56.3M | $51.0M | $53.8M | $53.0M | $46.3M | $40.4M | $41.1M |
| Inventory | $80.9M | $74.2M | $68.7M | $67.5M | $67.3M | $52.7M | $48.2M | $45.1M |
| Property, plant & equipment | $4.8M | $5.0M | $4.9M | $4.9M | $5.3M | $5.3M | $5.6M | $5.6M |
| Goodwill | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M |
| Intangible assets | $82.7M | $85.4M | $88.1M | $90.8M | $93.5M | $96.2M | $98.9M | $101.6M |
| Other non-current assets | $5.0M | $5.1M | $5.2M | $5.3M | $5.1M | $5.1M | $5.4M | $5.4M |
| Accounts payable | $9.3M | $11.5M | $3.1M | $6.5M | $9.5M | $6.4M | $2.3M | $7.5M |
| Accrued liabilities | $39.7M | $32.3M | $33.2M | $30.4M | $25.0M | $20.1M | $27.7M | $23.5M |
| Short-term debt | $63.8M | — | $0 | $0 | $0 | $12.0M | $15.1M | $15.1M |
| Other current liabilities | $5.0M | $4.4M | $4.9M | $2.6M | $1.6M | $156.0K | $1.1M | $678.0K |
| Long-term debt | $188.8M | $221.2M | $220.3M | $219.5M | $218.6M | $217.8M | $217.0M | — |
| Other non-current liabilities | $12.7M | $8.1M | $8.4M | $3.4M | $7.8M | $4.8M | $2.0M | $8.5M |
| Common stock & paid-in capital | $18.0K | $18.0K | $17.0K | $17.0K | $16.0K | $16.0K | $15.0K | $15.0K |
| Retained earnings | -$700.2M | -$669.1M | -$671.3M | -$682.4M | -$683.0M | -$681.1M | -$671.9M | -$666.7M |
| Accumulated other comprehensive income (loss) | -$10.0K | -$24.0K | -$25.0K | -$25.0K | -$24.0K | -$25.0K | -$25.0K | -$16.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.3M | $9.9M | $20.0M | $18.4M | $182.0K | -$10.0M | $2.0M | -$8.3M |
| Investing cash flow | -$209.0K | -$325.0K | -$333.0K | -$71.0K | -$279.0K | -$13.0K | $10.0M | $9.9M |
| Financing cash flow | $1.9M | -$8.8M | -$266.0K | $13.8M | $942.0K | -$3.1M | $398.0K | -$83.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $323.0K | $337.0K | $335.0K | $338.0K | $325.0K | $315.0K | $313.0K | $307.0K |
| Share-based compensation | $11.1M | $4.1M | $5.3M | $7.6M | $5.0M | $4.4M | $3.6M | $6.8M |
| Deferred income taxes | — | — | $0 | $0 | $0 | $0 | $0 | -$3.3M |
| Change in accounts receivable | $1.8M | $5.2M | -$2.7M | $703.0K | $6.7M | $5.9M | -$723.0K | -$1.3M |
| Change in inventory | $9.5M | -$851.0K | $4.0M | $4.1M | $7.6M | $3.6M | $3.1M | $1.0M |
| Change in accounts payable | $286.0K | $4.2M | -$1.7M | $2.0M | -$4.4M | $4.1M | -$5.2M | $1.7M |
| Purchases of investments | — | — | $0 | $0 | $0 | $0 | $0 | $5.0M |
| Debt issued | — | — | — | — | — | — | $0 | — |
| Debt repaid | — | — | — | — | — | — | $0 | — |
| Tax withholding on stock comp | $191.0K | $17.0M | $1.5M | $478.0K | $860.0K | $8.0M | $166.0K | $83.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M |
| Net income | $554.0K | -$54.8M | -$62.3M | -$94.7M | -$122.7M |
| EPS (diluted) | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
| EPS (basic) | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 |
| Operating margin | $9 | -$17 | -$27 | -$74 | -$232 |
| Net margin | $0 | -$27 | -$38 | -$86 | -$247 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M |
| Stockholders' equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M |
| Total current assets | $240.3M | $167.7M | $156.3M | $186.8M | $142.6M |
| Total current liabilities | $109.6M | $100.4M | $95.2M | $73.6M | $79.0M |
| Cash & equivalents | $111.0M | $71.6M | $67.4M | $122.0M | $67.3M |
| Marketable securities (current) | — | $0 | $5.0M | $0 | $35.2M |
| Accounts receivable | $51.0M | $40.4M | $39.2M | $30.8M | $17.5M |
| Inventory | $68.7M | $48.2M | $38.8M | $24.7M | $18.1M |
| Property, plant & equipment | $4.9M | $5.6M | $6.0M | $5.5M | $6.6M |
| Goodwill | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M |
| Intangible assets | $88.1M | $98.9M | $109.8M | $120.6M | $131.4M |
| Other non-current assets | $5.2M | $5.4M | $4.5M | $4.7M | $829.0K |
| Accounts payable | $3.1M | $2.3M | $11.6M | $4.6M | $8.9M |
| Accrued liabilities | $33.2M | $27.7M | $23.5M | $36.8M | $49.1M |
| Short-term debt | $0 | $15.1M | $0 | — | — |
| Other current liabilities | $4.9M | $1.1M | $1.2M | $2.7M | $2.0M |
| Long-term debt | $220.3M | $217.0M | $190.9M | — | — |
| Other non-current liabilities | $8.4M | $2.0M | $4.8M | $31.0K | $1.7M |
| Common stock & paid-in capital | $17.0K | $15.0K | $14.0K | $14.0K | $13.0K |
| Retained earnings | -$671.3M | -$671.9M | -$617.0M | -$554.8M | -$460.1M |
| Accumulated other comprehensive income (loss) | -$25.0K | -$25.0K | -$25.0K | -$23.0K | -$31.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M |
| Investing cash flow | -$696.0K | $4.9M | -$6.0M | $34.5M | $98.0M |
| Financing cash flow | $11.4M | $36.2M | -$1.6M | $127.5M | $27.2M |
| Free cash flow | — | — | — | — | -$96.6M |
| Capital expenditures | — | — | — | — | $1.1M |
| Depreciation & amortization | $1.3M | $1.2M | $1.5M | $1.4M | $1.3M |
| Share-based compensation | $22.4M | $18.4M | $10.7M | $12.2M | $11.4M |
| Deferred income taxes | $0 | -$2.3M | -$1.2M | -$1.4M | $0 |
| Change in accounts receivable | $10.6M | $1.2M | $8.4M | $13.4M | $6.2M |
| Change in inventory | $19.3M | $8.8M | $14.8M | $7.5M | $7.4M |
| Change in accounts payable | -$69.0K | -$9.6M | $7.0M | -$4.3M | $5.5M |
| Purchases of investments | $0 | $34.5M | $43.7M | $0 | $43.0M |
| Debt issued | — | $0 | $0 | $146.2M | $0 |
| Debt repaid | — | $0 | $0 | $43.5M | $0 |
| Tax withholding on stock comp | $10.9M | $3.7M | $1.0M | $468.0K | $534.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding XERS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:04 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-09 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-01 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-12 | View on SEC.gov → |
Recent news
Headlines about XERS (Xeris Biopharma Holdings, Inc.). Links open the publisher — we don’t host full articles.
-
XERS Nov 2026 9.000 put (XERS261120P00009000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Xeris Biopharma Holdings Inc (XERS) Shares Surge 6.2% -- What GF Score of 65 Tells Investors
GuruFocus · 2026-10-20 -
XERS Nov 2026 12.500 put (XERS261120P00012500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19 -
XERS Nov 2026 12.500 put (XERS261120P00012500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
Gen Xers share 17 nostalgic dishes they ate growing up—and still make for dinner
Upworthy · 2026-10-19 -
(XERS) Risk Channels and Responsive Allocation
Stock Traders Daily · 2026-10-19 -
Form 144 XERIS BIOPHARMA HOLDINGS For: 18 October By Investing.com
Investing.com Canada · 2026-10-19 -
Xeris files KEVEYIS suits. Barclays lifts target for Xeris Biopharma Holdings stock
AD HOC NEWS · 2026-10-18
No headlines in this category right now — try “All”.